Who Owns CRISPR Therapeutics Stock?
NASDAQ: CRSPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 79.17%
- Held by insiders
- 6.01%
- Institutional holders
- 682
- Institutions 79.2%
- Insiders 6.0%
- Public and other 14.8%
Who owns CRISPR Therapeutics stock?
Institutional investors own about 79.2% of CRISPR Therapeutics's shares, spread across 682 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 6.01% of CRSP.
The largest institutional holders are ARK Investment Management, LLC (10.37%), Blackrock Inc. (8.56%) and Orbis Allan Gray Ltd (5.62%). Together, the top 10 institutions control 46.1% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their CRSP positions and 5 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CRSP
| Institution | Shares | % Held | Change |
|---|---|---|---|
| ARK Investment Management, LLC | 10.06M | 10.37% | +6.3% |
| Blackrock Inc. | 8.30M | 8.56% | -0.6% |
| Orbis Allan Gray Ltd | 5.45M | 5.62% | -10.8% |
| State Street Corporation | 4.99M | 5.15% | +15.6% |
| Capital World Investors | 4.74M | 4.89% | -0.2% |
| GSK plc | 2.61M | 2.69% | -19.0% |
| Geode Capital Management, LLC | 2.51M | 2.59% | +0.1% |
| T. Rowe Price Investment Management, Inc. | 2.05M | 2.12% | -30.5% |
| SR One Capital Management, LP | 2.04M | 2.10% | 0.0% |
| Two Sigma Investments, LP | 1.99M | 2.05% | +34.1% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CRSP
| Fund | Shares | % Held |
|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 5.38M | 5.55% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.72M | 2.80% |
| iShares Trust-iShares Russell 2000 ETF | 2.33M | 2.40% |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.28M | 2.35% |
| NEW PERSPECTIVE FUND | 1.94M | 2.00% |
| SmallCap World Fund Inc | 1.69M | 1.75% |
| Growth Fund of America | 1.41M | 1.46% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.11M | 1.14% |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 1.05M | 1.08% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.02M | 1.05% |
Frequently asked questions
Who is the largest shareholder of CRISPR Therapeutics?
ARK Investment Management, LLC is the largest institutional shareholder of CRSP, owning 10.37% of shares outstanding (10.06M shares) as of its latest 13F filing.
What percentage of CRISPR Therapeutics is owned by institutions?
Institutions own about 79.2% of CRSP shares and 84.2% of the public float.
How much of CRISPR Therapeutics do insiders own?
Insiders, such as officers and directors, own about 6.01% of CRSP shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.